HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
15
08
2018
accepted:
03
12
2018
pubmed:
12
1
2019
medline:
6
8
2019
entrez:
12
1
2019
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland-bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used. The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative tool designed for rapid assessment of HS burden and, at the same time, an intuitive graphic visualization of the measurement outcome. A multicentre, longitudinal, observational study was conducted to validate the HIDRAdisk compared with other validated questionnaires [Skindex-16, Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment-General Health (WPAI:GH)] and to evaluate its correlation with disease severity in Italian patients with any degree of HS severity, as measured by Hurley stage and HS Physician Global Assessment (HS-PGA). A total of 140 patients (59% women; mean age 34.9 ± 11.0 years) were enrolled in 27 dermatologic centres. HIDRAdisk showed a strong correlation with Skindex-16 and DLQI, and a good one with WPAI:GH (correlation coefficient: 0.7568, 0.6651 and 0.5947, respectively) and a statistically significant correlation with both Hurley stage and HS-PGA. Very good internal consistency (Cronbach coefficient >0.80; intraclass correlation coefficient >0.6), with correlation between the 10 items, good test-retest reliability (Spearman correlation coefficient, 0.8331; P < 0.0001) and responsiveness to changes were demonstrated. Our study shows that HIDRAdisk, a short and innovative visual HS QoL instrument, has been psychometrically validated in Italian language and it may help improve the management of HS once implemented in routine clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland-bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used.
OBJECTIVE
OBJECTIVE
The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative tool designed for rapid assessment of HS burden and, at the same time, an intuitive graphic visualization of the measurement outcome.
METHODS
METHODS
A multicentre, longitudinal, observational study was conducted to validate the HIDRAdisk compared with other validated questionnaires [Skindex-16, Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment-General Health (WPAI:GH)] and to evaluate its correlation with disease severity in Italian patients with any degree of HS severity, as measured by Hurley stage and HS Physician Global Assessment (HS-PGA).
RESULTS
RESULTS
A total of 140 patients (59% women; mean age 34.9 ± 11.0 years) were enrolled in 27 dermatologic centres. HIDRAdisk showed a strong correlation with Skindex-16 and DLQI, and a good one with WPAI:GH (correlation coefficient: 0.7568, 0.6651 and 0.5947, respectively) and a statistically significant correlation with both Hurley stage and HS-PGA. Very good internal consistency (Cronbach coefficient >0.80; intraclass correlation coefficient >0.6), with correlation between the 10 items, good test-retest reliability (Spearman correlation coefficient, 0.8331; P < 0.0001) and responsiveness to changes were demonstrated.
CONCLUSION
CONCLUSIONS
Our study shows that HIDRAdisk, a short and innovative visual HS QoL instrument, has been psychometrically validated in Italian language and it may help improve the management of HS once implemented in routine clinical practice.
Identifiants
pubmed: 30633405
doi: 10.1111/jdv.15425
pmc: PMC6593467
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Validation Study
Langues
eng
Pagination
766-773Subventions
Organisme : AbbVie
Informations de copyright
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Cutan Med Surg. 2001 Mar-Apr;5(2):105-10
pubmed: 11443481
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Dermatol Ther. 2008 Jan-Feb;21(1):54-9
pubmed: 18318886
Acta Derm Venereol. 2010 May;90(3):264-8
pubmed: 20526543
Acta Derm Venereol. 2011 May;91(3):328-32
pubmed: 21394419
J Am Acad Dermatol. 2012 Sep;67(3):422-8, 428.e1
pubmed: 22182915
N Engl J Med. 2012 Jan 12;366(2):158-64
pubmed: 22236226
Dermatol Clin. 2012 Apr;30(2):231-6, xiii
pubmed: 22284137
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):473-8
pubmed: 22339940
Ann Intern Med. 2012 Dec 18;157(12):846-55
pubmed: 23247938
JAMA. 2013 Jun 12;309(22):2327-8
pubmed: 23757080
Br J Dermatol. 2014 Dec;171(6):1434-42
pubmed: 25040429
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):725-31
pubmed: 25229692
Am J Clin Dermatol. 2015 Feb;16(1):61-5
pubmed: 25432664
J Dermatolog Treat. 2018 Mar;29(2):152-164
pubmed: 28608738
J Am Acad Dermatol. 2018 Jan;78(1):215-217.e2
pubmed: 29241793
JAMA Dermatol. 2018 Mar 1;154(3):330-335
pubmed: 29417136
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e24-e26
pubmed: 29894009
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378